Literature DB >> 24582884

Inhibitors of NF-kappaB reverse cellular invasion and target gene upregulation in an experimental model of aggressive oral squamous cell carcinoma.

Jeff Johnson1, Zonggao Shi1, Yueying Liu1, M Sharon Stack2.   

Abstract

BACKGROUND: Oral squamous cell carcinoma (OSCC) is diagnosed in 640,000 patients yearly with a poor (50%) 5-year survival rate that has not changed appreciably in decades. PAITENTS AND METHODS: To investigate molecular changes that drive OSCC progression, cDNA microarray analysis was performed using human OSCC cells that form aggressive poorly differentiated tumors (SCC25-PD) in a murine orthotopic xenograft model compared to cells that produce well-differentiated tumors (SCC25-WD).
RESULTS: As this analysis revealed that 59 upregulated genes were NF-κB target genes, the role of NF-κB activation in alteration of the transcriptional profile was evaluated. The mRNA and protein upregulation of a panel NF-κB target genes was validated by real-time qPCR and immunohistochemistry. Additionally, nuclear translocation of RelA was greatly increased in SCC25-PD, increased nuclear RelA was observed in oral tumors initiated with SCC25-PD compared with tumors initiated by SCC25-WD, and nuclear RelA correlated with stage of disease on two human OSCC tissue microarrays. Treatment of SCC25-PD cells with the IKKβ-inhibitor sc-514, that effectively prevents RelA phosphorylation on Ser 536, reversed nuclear-translocation of RelA and strongly inhibited NF-κB gene activation. Furthermore, blocking the phosphorylation of RelA using the MSK1/2 inhibitor SB 747651A significantly reduced the mRNA upregulation of a subset of target genes. Treatment with sc-514 or SB747651A markedly diminished cellular invasiveness.
CONCLUSIONS: These studies support a model wherein NF-κB is constitutively active in aggressive OSCC, while blocking the NF-κB pathway reduces NF-κB target gene upregulation and cellular invasiveness.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Immunohistochemistry; Invasion; NF-kappaB (NF-κB); Oral cancer; Transcriptional regulation

Mesh:

Substances:

Year:  2014        PMID: 24582884      PMCID: PMC4001858          DOI: 10.1016/j.oraloncology.2014.02.004

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  49 in total

1.  Clinicopathological parameters, recurrence, locoregional and distant metastasis in 115 T1-T2 oral squamous cell carcinoma patients.

Authors:  Waseem Jerjes; Tahwinder Upile; Aviva Petrie; Andrew Riskalla; Zaid Hamdoon; Michael Vourvachis; Kostas Karavidas; Amrita Jay; Ann Sandison; Gareth J Thomas; Nicholas Kalavrezos; Colin Hopper
Journal:  Head Neck Oncol       Date:  2010-04-20

Review 2.  NF-κB addiction and its role in cancer: 'one size does not fit all'.

Authors:  M M Chaturvedi; B Sung; V R Yadav; R Kannappan; B B Aggarwal
Journal:  Oncogene       Date:  2010-12-20       Impact factor: 9.867

Review 3.  NF-κB as a target for pancreatic cancer therapy.

Authors:  Carmine Carbone; Davide Melisi
Journal:  Expert Opin Ther Targets       Date:  2012-03-23       Impact factor: 6.902

4.  Urinary-type plasminogen activator receptor/alpha 3 beta 1 integrin signaling, altered gene expression, and oral tumor progression.

Authors:  Supurna Ghosh; Jennifer Koblinski; Jeffrey Johnson; Yueying Liu; Aaron Ericsson; J Wade Davis; Zonggao Shi; Matthew J Ravosa; Susan Crawford; Shellaine Frazier; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2010-02-09       Impact factor: 5.852

5.  Selective inhibition of nuclear factor-κB by nuclear factor-κB essential modulator-binding domain peptide suppresses the metastasis of highly metastatic oral squamous cell carcinoma.

Authors:  Takuya Tanaka; Hideki Nakayama; Yoshihiro Yoshitake; Atsushi Irie; Masashi Nagata; Kenta Kawahara; Yasuo Takamune; Ryoji Yoshida; Yoshihiro Nakagawa; Hidenao Ogi; Satoru Shinriki; Kazutoshi Ota; Akimitsu Hiraki; Tetsuro Ikebe; Yasuharu Nishimura; Masanori Shinohara
Journal:  Cancer Sci       Date:  2012-01-16       Impact factor: 6.716

6.  Characterization of the cellular action of the MSK inhibitor SB-747651A.

Authors:  Shaista Naqvi; Andrew Macdonald; Claire E McCoy; Joanne Darragh; Alastair D Reith; J Simon C Arthur
Journal:  Biochem J       Date:  2012-01-01       Impact factor: 3.857

7.  Pim-1 controls NF-kappaB signalling by stabilizing RelA/p65.

Authors:  K Nihira; Y Ando; T Yamaguchi; Y Kagami; Y Miki; K Yoshida
Journal:  Cell Death Differ       Date:  2009-11-13       Impact factor: 15.828

Review 8.  The diverse and complex roles of NF-κB subunits in cancer.

Authors:  Neil D Perkins
Journal:  Nat Rev Cancer       Date:  2012-01-19       Impact factor: 60.716

9.  Correlation of NF-kappaB signal pathway with tumor metastasis of human head and neck squamous cell carcinoma.

Authors:  Ming Yan; Qin Xu; Ping Zhang; Xiao-jian Zhou; Zhi-yuan Zhang; Wan-tao Chen
Journal:  BMC Cancer       Date:  2010-08-17       Impact factor: 4.430

10.  Mitogen- and stress-activated kinase 1 (MSK1) regulates cigarette smoke-induced histone modifications on NF-κB-dependent genes.

Authors:  Isaac K Sundar; Sangwoon Chung; Jae-Woong Hwang; John D Lapek; Michael Bulger; Alan E Friedman; Hongwei Yao; James R Davie; Irfan Rahman
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

View more
  8 in total

Review 1.  Advances in Immunosuppressive Agents Based on Signal Pathway.

Authors:  Zhiqing Xu; Ming Chu
Journal:  Front Pharmacol       Date:  2022-05-26       Impact factor: 5.988

2.  Decrease of miR-146a is associated with the aggressiveness of human oral squamous cell carcinoma.

Authors:  Zonggao Shi; Jeffrey J Johnson; Rong Jiang; Yueying Liu; M Sharon Stack
Journal:  Arch Oral Biol       Date:  2015-06-20       Impact factor: 2.633

3.  Protease-activated Receptor-2 (PAR-2)-mediated Nf-κB Activation Suppresses Inflammation-associated Tumor Suppressor MicroRNAs in Oral Squamous Cell Carcinoma.

Authors:  Jeff J Johnson; Daniel L Miller; Rong Jiang; Yueying Liu; Zonggao Shi; Laura Tarwater; Russell Williams; Rashna Balsara; Edward R Sauter; M Sharon Stack
Journal:  J Biol Chem       Date:  2016-02-02       Impact factor: 5.157

4.  IκB kinase b Mediating the Downregulation of p53 and p21 by Lipopolysaccharide in Human Papillomavirus 16+ Cervical Cancer Cells.

Authors:  Zhi-Hui Tan; Yu Zhang; Yan Tian; Wei Tan; Ying-Hua Li
Journal:  Chin Med J (Engl)       Date:  2016-11-20       Impact factor: 2.628

5.  MicroRNA‑199a‑5p functions as a tumor suppressor in oral squamous cell carcinoma via targeting the IKKβ/NF‑κB signaling pathway.

Authors:  Dongyi Wei; Baohong Shen; Weixin Wang; Yanjun Zhou; Xiaodong Yang; Guangjian Lu; Jianbin Yang; Yuebao Shao
Journal:  Int J Mol Med       Date:  2019-01-29       Impact factor: 4.101

6.  Inhibition of kinase IKKβ suppresses cellular abnormalities induced by the human papillomavirus oncoprotein HPV 18E6.

Authors:  Mojgan Padash Barmchi; Miranda Thomas; Jayashree V Thatte; Arushi Vats; Bing Zhang; Ross L Cagan; Lawrence Banks
Journal:  Sci Rep       Date:  2021-01-13       Impact factor: 4.379

7.  The multi-target small-molecule inhibitor SB747651A shows in vitro and in vivo anticancer efficacy in glioblastomas.

Authors:  Arnon Møldrup Knudsen; Henning Bünsow Boldt; Elisabeth Victoria Jakobsen; Bjarne Winther Kristensen
Journal:  Sci Rep       Date:  2021-03-16       Impact factor: 4.379

Review 8.  Targeting IKKβ in Cancer: Challenges and Opportunities for the Therapeutic Utilisation of IKKβ Inhibitors.

Authors:  Jack A Prescott; Simon J Cook
Journal:  Cells       Date:  2018-08-23       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.